163 products. Four tiers. One dossier request away.

The catalog is organized around two axes that determine what a buyer can request: product type (finished dosage form vs. active pharmaceutical ingredient) and market tier (export vs. domestic). FDF Export covers 53 finished-dose products cleared for SRA and Rest-of-World export markets; FDF Domestic covers 58 finished-dose products for the Indian market. API Export covers 63 active ingredients — supplied by MacChem, a group company — for international buyers; API Domestic covers the same 63 APIs for Indian formulators. A single molecule can appear in more than one tier where both a finished dose and its API are manufactured.

This catalog page and the searchable product index that follows list what Naprod manufactures; they do not publish technical specifications, stability data, or CoAs. Every listing routes through an enquiry: submit a product and market, and the regulatory team responds with current dossier status, registration coverage, and next steps. This keeps commercially and regulatorily sensitive detail — batch data, filing status by country, pricing — off the public site while still making the full catalog searchable.

Pending approval Dossier status shown per product in the catalog index is drawn from internal dossier tracking and has not been independently reconciled against each national regulator's public register — treat as a starting point for enquiry, not a filing guarantee.

A subset of the oncology and anesthesia catalog falls under national controlled-substance or narcotic scheduling in one or more destination markets. Handling, export documentation, and buyer-side licensing requirements vary by country and are confirmed case-by-case at enquiry stage.

Pending approval PENDING APPROVAL — company/legal sign-off on which specific SKUs are flagged controlled, and the country-by-country handling language, has not been finalized. No SKU-level controlled-substance claims are made on this page until that review closes.